PHOXILLUM BK4/2.5 calcium chloride, magnesium chloride, sodium chloride, sodium bicarbonate, potassium chloride, and sodium phosphate dibasic dihydrate 3.68 g/L; 3.05 g/L; 6.34 g/L; 3.09 g/L; .314 g/L; .187 g/L Injection — NDC 24571-116-06 (Billing 24571-0116-06)
This is a package of PHOXILLUM BK4/2.5 calcium chloride, magnesium chloride, sodium chloride, sodium bicarbonate, potassium chloride, and sodium phosphate dibasic dihydrate 3.68 g/L; 3.05 g/L; 6.34 g/L; 3.09 g/L; .314 g/L; .187 g/L Injection from Vantive US Healthcare LLC, marketed since Jan 2015 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 24571-116-06 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 24571 labeler · 116 product · 06 package
- Package marketed since
- Jan 13, 2015
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 2457111606 0
- FDA record last changed
- Oct 1, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 075392
- GCN: 40478
- HICL (First Databank): 042959
- AHFS class code: 40:12.00.00
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 3, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 3, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 4, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 24571-0116-06 You're viewing this Main listing | 2 BAG in 1 CASE / 5 L in 1 BAG | 2015-01-13 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Phoxillum Bk4/2.5 3.68 g/L; 3.05 g/L; 6.34 g/L; 3.09 g/L; .314 g/L; .187 g/Lthis 24571-0116-06 | Vantive | 5 l | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 142M471B3J
Carbon dioxide is a colorless gas used in medicines as a propellant in pressurized inhalers and aerosol sprays to help deliver the active medication to where it's needed.
-
UNII QTT17582CB
A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
3 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 3, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Vantive US Healthcare LLC labeler code 24571
- PRISMASOL BGK2/3.5 calcium chloride, magnesium chloride, dextrose anhydrous, lactic acid, sodium chloride, sodium bicarbonate, and potassium chloride 5.15 g/L; 2.03 g/L; 20 g/L; 5.4 g/L; 6.46 g/L; 3.09 g/L; .157 g/L Injection NDC 24571-103-06
- PRISMASOL BGK4/2.5 calcium chloride, magnesium chloride, dextrose anhydrous, lactic acid, sodium chloride, sodium bicarbonate, and potassium chloride 3.68 g/L; 3.05 g/L; 20 g/L; 5.4 g/L; 6.46 g/L; 3.09 g/L; .314 g/L Injection NDC 24571-105-06
- PRISMASOL BGK0/2.5 calcium chloride, magnesium chloride, dextrose anhydrous, lactic acid, sodium chloride, and sodium bicarbonate 3.68 g/L; 3.05 g/L; 20 g/L; 5.4 g/L; 6.46 g/L; 3.09 g/L Injection NDC 24571-108-06
- PRISMASOL B22GK4/0 magnesium chloride, dextrose anhydrous, lactic acid, sodium chloride, sodium bicarbonate, and potassium chloride 3.05 g/L; 20 g/L; 5.4 g/L; 7.07 g/L; 2.21 g/L; .314 g/L Injection NDC 24571-111-06
- PRISMASOL BK0/0/1.2 magnesium chloride, lactic acid, sodium chloride, and sodium bicarbonate 2.44 g/L; 5.4 g/L; 6.46 g/L; 3.09 g/L Injection NDC 24571-113-06
- PRISMASOL BGK4/0/1.2 magnesium chloride, dextrose anhydrous, lactic acid, sodium chloride, sodium bicarbonate, and potassium chloride 2.44 g/L; 20 g/L; 5.4 g/L; 6.46 g/L; 3.09 g/L; .314 g/L Injection NDC 24571-114-06
- PHOXILLUM B22K4/0 magnesium chloride, sodium chloride, sodium bicarbonate, potassium chloride, and sodium phosphate dibasic dihydrate 3.05 g/L; .314 g/L; 2.21 g/L; 6.95 g/L; .187 g/L Injection NDC 24571-117-06
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances. PRISMASOL and PHOXILLUM solutions are indicated: • As a replacement solution in Continuous Renal Replacement Therapy (CRRT) and in case of drug poisoning when CRRT is used to remove dialyzable substances ( 1 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION • Therapy must be individualized based on the patient's clinical condition, fluid, electrolyte, acid-base and glucose balance ( 2.2 ) • Solution must be mixed prior to use ( 2.2 ) • Use only with extracorporeal dialysis equipment appropriate for CRRT ( 2.3 )
2.1Administration Instructions Visually inspect PRISMASOL and PHOXILLUM for particulate matter and discoloration prior to administration. Administration should only be under the direction of a physician competent in intensive care treatment including CRRT. Use only with extracorporeal dialysis equipment appropriate for CRRT.
The prepared solution is for single patient use only. Aseptic technique should be used throughout administration to the patient. Discard any unused solution.
2.2Dosing Considerations PRISMASOL replacement solutions contain 4 different combinations of active ingredients (7 different products with varying ingredient amounts). PHOXILLUM replacement solutions contain 2 different combinations of active ingredients (2 different products with varying ingredient amounts). PRISMASOL and PHOXILLUM are supplied in a two-compartment bag that must be mixed immediately prior to use [see Dosage and Administration (2.3) ]: • Small compartment A (250 mL) containing an electrolyte solution, and • Large compartment B (4750 mL) containing the buffer solution.
See Table 1 for the concentrations of the active ingredients (after mixing) in these 9 different replacement solutions (total volume is 5 Liters). Table 1: Concentrations of Active Ingredients in the 7 PRISMASOL and 2 PHOXILLUM Replacement Solutions after Mixing Ca 2+ mEq/L HCO 3 - mEq/L K + mEq/L Mg 2+ mEq/L Na + mEq/L HPO 4 2- mmol/L Cl - mEq/L Lactate mEq/L Dextrose mg/dL Osmolarity mOsm/L Ca 2+ = calcium, HCO 3 - = bicarbonate, K + = potassium, Mg 2+ = magnesium, Na + = sodium, HPO 4 2- = phosphate, Cl- = chloride; osmolarity is estimated PRISMASOL Replacement Solutions BGK0/2.5 2.5 32 0 1.5 140 0 109 3 100 292 BGK4/2.5 2.5 32 4 1.5 140 0 113 3 100 300 BGK2/3.5 3.5 32 2 1 140 0 111.5 3 100 296 BGK2/0 0 32 2 1 140 0 108 3 100 291 B22GK4/0 0 22 4 1.5 140 0 120.5 3 100 296 BGK4/0/1.2 0 32 4 1.2 140 0 110.2 3 100 295 BK0/0/1.2 0 32 0 1.2 140 0 106.2 3 0 282 PHOXILLUM Replacement Solutions BK4/2.5 2.5 32 4 1.5 140 1 114.5 0 0 294 B22K4/0 0 22 4 1.5 140 1 122 0 0 290 The mode of therapy, solute formulation, flow rates, and length of PRISMASOL and PHOXILLUM replacement therapy in CRRT should be established by a physician based on the patient’s clinical condition, blood concentration of phosphate and other electrolytes, acid-base and glucose balance.
Administer either PRISMASOL or PHOXILLUM into the extracorporeal circuit: • Before (pre-dilution) the hemofilter or hemodiafilter, • After (post-dilution) the hemofilter or hemodiafilter, or • Before and after the hemofilter or hemodiafilter.
2.3Preparing the Solution Use only if the overwrap is not damaged, all seals are intact, peel seal is not broken, and the solution is clear. The solution may be warmed to 37°C/98.6°F prior to removing the overwrap to enhance patient comfort. However, only dry heat should be used.
Solutions should not be heated in water or in a microwave oven. After heating, verify that the solution remains clear and contains no particulate matter. The solutions are supplied in two different two-compartment bags made of polyolefin with a peel seal separating compartment A and B (see Figure 1 ).
Follow the instructions below when connecting the solution bags for correct use of the access ports. Instructions for preparing solutions supplied in a two-compartment, polyolefin bag with a peel seal: Figure 1 Figure 1 Figure 2 Step 1 Immediately before use, remove the overwrap from the bag and mix the solutions in the two different compartments. After removing the overwrap, inspect the bag for leakage by pressing firmly on the bag.
Discard the bag if any leakage is detected since sterility cannot be assured. As soon as the overwrap… [Excerpted — this section continues on DailyMed.]
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS See Table 1 for the concentrations of the active ingredients (after mixing) in these 9 different replacement solutions [see Dosage and Administration (2.2) ] . PRISMASOL and PHOXILLUM are available in multiple combinations of ingredients and in multiple variations of strengths. See full Prescribing Information for detailed descriptions of each formulation. ( 2 , 3 , 11 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS PHOXILLUM and PRISMASOL replacement solutions are contraindicated in patients with known hypersensitivities to these products. Known hypersensitivities to PRISMASOL and PHOXILLUM solutions ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS • Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorus, other electrolytes and acid-base balance. Abnormalities may be corrected by the use of appropriate formulations and dosage of PRISMASOL and PHOXILLUM solutions ( 5.1 ) • Treatment may affect glucose levels. Monitor blood glucose levels. • Antidiabetic therapy adjustment or other corrective measures may be required during treatment ( 5.2 ) To report SUSPECTED ADVERSE REACTIONS, contact Vantive US Healthcare LLC at 1855-857-0003 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
5.1Electrolyte and Volume Abnormalities PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately [ see Dosage and Administration (2) ].
PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis .
5.2Blood Glucose Abnormalities The use of PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following adverse reactions have been identified during postapproval use with these or other similar products and therefore may occur with use of PHOXILLUM or PRISMASOL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. • Metabolic acidosis • Hypotension • Acid-base disorders • Electrolyte imbalance including calcium ionized increased (reported in PRISMASOL solutions containing calcium), hyperphosphatemia, and hypophosphatemia • Fluid imbalance
🔄 Drug Interactions ▾
7 DRUG INTERACTIONS As with the use of other replacement solutions, blood concentrations of dialyzable drugs may be reduced by CRRT due to their removal by the hemofilter or hemodiafilter. The blood concentrations of certain drugs may need to be monitored and appropriate therapy implemented to correct for removal during treatment.
7.1Citrate When used as an anticoagulant, citrate contributes to the overall buffer load and can reduce plasma calcium levels. Select the PRISMASOL/PHOXILLUM formulation(s) accordingly.
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS
8.1Pregnancy Risk Summary PRISMASOL and PHOXILLUM are pharmacologically inactive solutions. While there are no adequate and well controlled studies in pregnant women, appropriate administration of PRISMASOL and PHOXILLUM solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm. Animal reproduction studies have not been conducted with PRISMASOL and PHOXILLUM solutions.
The estimated background risk of major birth defects and miscarriage for the indicated population are unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations Maintenance of normal acid-base balance is important for fetal well-being.
8.2Lactation Risk Summary The components of PRISMASOL and PHOXILLUM solutions are excreted in human milk. Appropriate administration of PRISMASOL and PHOXILLUM solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to harm a nursing infant.
8.4Pediatric Use Safety and effectiveness have been established based on published clinical data of CRRT replacement solutions with compositions similar to PRISMASOL and PHOXILLUM used in adults and two hemofiltration studies in pediatric patients, including a study of newborns to 17 years old.
8.5Geriatric Use The experience with PRISMASOL and PHOXILLUM solutions in geriatric patients has not identified novel concerns.
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary PRISMASOL and PHOXILLUM are pharmacologically inactive solutions. While there are no adequate and well controlled studies in pregnant women, appropriate administration of PRISMASOL and PHOXILLUM solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm. Animal reproduction studies have not been conducted with PRISMASOL and PHOXILLUM solutions.
The estimated background risk of major birth defects and miscarriage for the indicated population are unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations Maintenance of normal acid-base balance is important for fetal well-being.
🧒 Pediatric Use ▾
8.4Pediatric Use Safety and effectiveness have been established based on published clinical data of CRRT replacement solutions with compositions similar to PRISMASOL and PHOXILLUM used in adults and two hemofiltration studies in pediatric patients, including a study of newborns to 17 years old.
🧓 Geriatric Use ▾
8.5Geriatric Use The experience with PRISMASOL and PHOXILLUM solutions in geriatric patients has not identified novel concerns.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action PRISMASOL and PHOXILLUM solutions are pharmacologically inactive. The electrolyte concentrations in the solutions are chosen to restore plasma levels to clinically desired concentrations or maintain plasma levels at the desired concentrations. PRISMASOL and PHOXILLUM solutions are used as replacement solution to replace water and electrolytes removed during hemofiltration and hemodiafiltration.
Bicarbonate (or precursor lactate) in the solution is used as an alkalinizing buffer to restore acid-base balance to a clinically desirable level.
12.3Pharmacokinetics The distribution of electrolytes, bicarbonate, and dextrose is determined by the patient's clinical condition, metabolic status, and residual renal function. The elimination and replacement of water, electrolytes and buffer depend on the patient's electrolyte and acid-base balance, metabolic status, residual renal function and ongoing physiologic losses through intestinal, respiratory and cutaneous routes.
🧬 Mechanism of Action ▾
12.1Mechanism of Action PRISMASOL and PHOXILLUM solutions are pharmacologically inactive. The electrolyte concentrations in the solutions are chosen to restore plasma levels to clinically desired concentrations or maintain plasma levels at the desired concentrations. PRISMASOL and PHOXILLUM solutions are used as replacement solution to replace water and electrolytes removed during hemofiltration and hemodiafiltration.
Bicarbonate (or precursor lactate) in the solution is used as an alkalinizing buffer to restore acid-base balance to a clinically desirable level.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING PRISMASOL and PHOXILLUM solutions are supplied in a two-compartment bag made of polyolefin. The 5000 mL bag is composed of a small compartment (250 mL) and a large compartment (4750 mL). The two compartments are separated by a peel seal.
The bag is overwrapped with a transparent overwrap. See Table 2 for the concentrations of the active ingredients in each compartment for each product [see Description (11) ]. Container Fill Volume NDC PRISMASOL Solutions PRISMASOL BGK0/2.5 5000 mL 24571-108-06 PRISMASOL BGK4/2.5 5000 mL 24571-105-06 PRISMASOL BGK2/3.5 5000 mL 24571-103-06 PRISMASOL BGK2/0 5000 mL 24571-102-06 PRISMASOL B22GK4/0 5000 mL 24571-111-06 PRISMASOL BK0/0/1.2 5000 mL 24571-113-06 PRISMASOL BGK4/0/1.2 5000 mL 24571-114-06 PHOXILLUM Solutions PHOXILLUM BK4/2.5 5000 mL 24571-116-06 PHOXILLUM B22K4/0 5000 mL 24571-117-06 Not all formulations may be marketed.
Storage conditions Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF). [See USP Controlled Room Temperature] Do not freeze or expose to excessive heat. Do not use if precipitate has formed or if container seals have been damaged. Manufactured for: Vantive US Healthcare LLC Deerfield, Illinois 60015 07-19-00-9693 Vantive, Phoxillum and PrismaSol are trademarks of Vantive Health LLC, or its affiliates
📦 Storage and Handling ▾
Storage conditions Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF). [See USP Controlled Room Temperature] Do not freeze or expose to excessive heat. Do not use if precipitate has formed or if container seals have been damaged. Manufactured for: Vantive US Healthcare LLC Deerfield, Illinois 60015 07-19-00-9693 Vantive, Phoxillum and PrismaSol are trademarks of Vantive Health LLC, or its affiliates
📋 Description ▾
11 DESCRIPTION PRISMASOL and PHOXILLUM solutions are clear, sterile, free of bacterial endotoxins and contain no bacteriostatic or antimicrobial agents. These solutions are used in Continuous Renal Replacement Therapies (CRRT) as a replacement solution in hemofiltration and hemodiafiltration. Depending on the product (see Table 2 ), the two compartments contain: Calcium chloride, USP, is chemically designated calcium chloride dihydrate (CaCl 2 • 2H 2 O).
Magnesium chloride, USP, is chemically designated magnesium chloride hexahydrate (MgCl 2 • 6H 2 O). Sodium chloride, USP, is chemically designated NaCl. Potassium chloride, USP, is chemically designated KCl.
Sodium bicarbonate, USP, is chemically designated NaHCO 3 . Dextrose, USP, is chemically designated D-Glucose anhydrous (C 6 H 12 O 6 ) or D-Glucose monohydrate (C 6 H 12 O 6 • H 2 O). Lactic acid, USP, is chemically designated CH 3 CH(OH)COOH.
Dibasic sodium phosphate, USP, is chemically designated as disodium hydrogen phosphate, dihydrate (Na 2 HPO 4 • 2H 2 O) Table 2 - Compartment Composition (Before Mixing) Compartment A (g/L) Compartment B (g/L) Calcium Chloride ∙ 2H 2 O Magnesium Chloride ∙ 6H 2 O Dextrose anhydrous (as monohydrate) Lactic Acid Sodium Chloride Sodium bicarbonate Potassium Chloride Sodium Phosphate ∙ 2H 2 O PRISMASOL SOLUTIONS BGK 0/2.5 3.68 3.05 20 (22) 5.40 6.46 3.09 0 0 BGK 4/2.5 3.68 3.05 20 (22) 5.40 6.46 3.09 0.314 0 BGK 2/3.5 5.15 2.03 20 (22) 5.40 6.46 3.09 0.157 0 BGK 2/0 0 2.03 20 (22) 5.40 6.46 3.09 0.157 0 B22GK 4/0 0 3.05 20 (22) 5.40 7.07 2.21 0.314 0 BK 0/0/1.2 0 2.44 0 (0) 5.40 6.46 3.09 0 0 BGK 4/0/1.2 0 2.44 20 (22) 5.40 6.46 3.09 0.314 0 PHOXILLUM SOLUTIONS BK 4/2.5 3.68 3.05 0 (0) 0 6.34 3.09 0.314 0.187 B22K 4/0 0 3.05 0 (0) 0 6.95 2.21 0.314 0.187 The pH of the final solution is in the range of 7.0 to 8.5.
🧬 Pharmacokinetics ▾
12.3Pharmacokinetics The distribution of electrolytes, bicarbonate, and dextrose is determined by the patient's clinical condition, metabolic status, and residual renal function. The elimination and replacement of water, electrolytes and buffer depend on the patient's electrolyte and acid-base balance, metabolic status, residual renal function and ongoing physiologic losses through intestinal, respiratory and cutaneous routes.
📄 Package Label / Principal Display Panel ▾
Package/Label Display Panel Container Label Mixing steps ① SQUEEZE TOP corners to break seal ② Squeeze BAG SIDES to fully open seal Barcode NDC# 24571-108-06 OK + mEq/L
2.5Ca 2+ mEq/L PrismaSol BGK0/2.5 Rx only Barcode Replacement Solution for Continuous Renal Replacement Therapy Before reconstitution each 1000 mL contains (g) A B Calcium chloride • 2H 2 O
3.68 Magnesium chloride • 6H 2 O
3.05Dextrose anhydrous 20.0 (as dextrose monohydrate)
22.0 Sodium chloride
6.46 Lactic acid
5.40 Sodium bicarbonate
3.09Water for injections q.s, Carbon dioxide for pH adjustment A 250 mL B 4750 mL After reconstitution, A + B Calcium Ca 2+ Magnesium Mg 2+ Sodium Na + Chloride Cl - Lactate C 3 H 5 O 3 - Bicarbonate HCO 3 - Potassium K + Dextrose mmol/L 1.25 0.75 140 109.0 3.0 32 0 5.5 mEq/L 2.5 1.5 140 109.0 3.0 32 0 (100 mg/dL) Theoretical osmolarity: 292 mOsm/L pH: 7.0 –
8.5Mix both compartments before use. See package insert for dosage information and further instructions. Sterile and free from bacterial endotoxins.
Confirm the integrity of the packaging. Use only if solution is clear. For single use only.
DISCARD ANY UNUSED SOLUTION. Store at +20°C to +25°C (+68°F to +77°F); excursions permitted to +15°C to +30°C (+59°F to +86°F). [See USP Controlled room Temperature.] Do not freeze or expose to excessive heat. As soon as the overwrap is removed, the reconstitution of compartments A and B should be done and the reconstituted solution should be used immediately.
After removal of the overwrap, the solution is stable for 24 hours including the duration of the treatment. Mix additives BEFORE connecting this bag to the extracorporeal circuit. (See insert for further information.) This product is not made with natural rubber latex.
5000 mL EAN-14: 07332414091613 Product # 110240 VANTIVE Logo Batch No. and expiry date are printed on the back of the bag. Manufactured for: Vantive US Healthcare LLC Deerfield IL 60015 USA Made in Italy REPLACEMENT Solution for Continuous Renal Replacement Therapy 07-25-00-5278 Container Label Mixing steps ① SQUEEZE TOP corners to break seal ② Squeeze BAG SIDES to fully open seal Barcode NDC# 24571-105-06 4K + mEq/L
2.5Ca 2+ mEq/L PrismaSol BGK4/2.5 Rx only Barcode Replacement Solution for Continuous Renal Replacement Therapy Before reconstitution each 1000 mL contains (g) A B Calcium chloride • 2H 2 O
3.68 Magnesium chloride • 6H 2 O
3.05Dextrose anhydrous 20.0 (as dextrose monohydrate)
22.0 Sodium chloride
6.46Potassium chloride 0.314 Lactic acid
5.40 Sodium bicarbonate
3.09Water for injections q.s, Carbon dioxide for pH adjustment A 250 mL B 4750 mL After reconstitution, A + B Calcium Ca 2+ Magnesium Mg 2+ Sodium Na + Chloride Cl - Lactate C 3 H 5 O 3 - Bicarbonate HCO 3 - Potassium K + Dextrose mmol/L 1.25 0.75 140 113.0 3.0 32 4.0 5.5 mEq/L 2.5 1.5 140 113.0 3.0 32 4.0 (100 mg/dL) Theoretical osmolarity: 300 mOsm/L pH: 7.0 –
8.5Mix both compartments before use. See package insert for dosage information and further instructions. Sterile and free from bacterial endotoxins.
Confirm the integrity of the packaging. Use only if solution is clear. For single use only.
DISCARD ANY UNUSED SOLUTION. Store at +20°C to +25°C (+68°F to +77°F); excursions permitted to +15°C to +30°C (+59°F to +86°F). [See USP Controlled room Temperature.] Do not freeze or expose to excessive heat. As soon as the overwrap is removed, the reconstitution of compartments A and B should be done and the reconstituted solution should be used immediately.
After removal of the overwrap, the solution is stable for 24 hours including the duration of the treatment. Mix additives BEFORE connecting this bag to the extracorporeal circuit. (See insert for further information.) This product is not made with natural rubber latex.
5000 mL EAN-14: 07332414091637 Product # 110242 VANTIVE Logo Batch No. and expiry date are printed on the back of the bag. Manufactured for: Vantive US Healthcare LLC Deerfield IL 60015 USA Made in Italy REPLACEMENT Solution… [Excerpted — this section continues on DailyMed.]
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |